BioNTech Oncology Faces $1B Buyback Warning Before ASCO
Can BioNTech Oncology turn its huge cash pile into a real cancer breakthrough before investors lose patience?
BioNTech Leadership Change: -17.9% Crash After Billion-Euro Loss
Can BioNTech’s surprise leadership change and deepening losses turn a Covid-era star into a long-term oncology value play or a value trap? How did markets react to BioNTech…